Ginkgo Bioworks Holdings, Inc.
NYSE•DNA
CEO: Dr. Jason Kelly Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-04-19
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Contact Information
Market Cap
$515.41M
P/E (TTM)
-1.5
9.8
Dividend Yield
--
52W High
$17.58
52W Low
$5.37
52W Range
Rank66Top 96.8%
1.5
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 1.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data